Last reviewed · How we verify

Budesonide + Salmeterol + Montelukast — Competitive Intelligence Brief

Budesonide + Salmeterol + Montelukast (Budesonide + Salmeterol + Montelukast) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: inhaled corticosteroid + long-acting beta-2 agonist + leukotriene receptor antagonist. Area: Respiratory / Pulmonolo

marketed Combination therapy: inhaled corticosteroid + long-acting beta-2 agonist + leukotriene receptor antagonist Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (salmeterol); cysteinyl leukotriene receptors CysLT1 and CysLT2 (montelukast) Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Budesonide + Salmeterol + Montelukast (Budesonide + Salmeterol + Montelukast) — National Heart, Lung, and Blood Institute (NHLBI). This combination reduces airway inflammation via corticosteroid action, dilates airways through beta-2 agonist stimulation, and blocks leukotriene-mediated inflammatory pathways.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Budesonide + Salmeterol + Montelukast TARGET Budesonide + Salmeterol + Montelukast National Heart, Lung, and Blood Institute (NHLBI) marketed Combination therapy: inhaled corticosteroid + long-acting beta-2 agonist + leukotriene receptor antagonist Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (salmeterol); cysteinyl leukotriene receptors CysLT1 and CysLT2 (montelukast)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: inhaled corticosteroid + long-acting beta-2 agonist + leukotriene receptor antagonist class)

  1. National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Budesonide + Salmeterol + Montelukast — Competitive Intelligence Brief. https://druglandscape.com/ci/budesonide-salmeterol-montelukast. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: